Proactive Investors - Run By Investors For Investors

AusCann Group gets regulatory nod to supply medicinal cannabis products in Chile

Special access scheme will accelerate the plan to supply medicinal cannabis products.
medicinal cannabis products
Similar access scheme is used in Australia

AusCann Group Holdings Ltd (ASX:AC8) has achieved a major breakthrough following the establishment of a special access scheme which enables access for Chilean patients to medicinal cannabis products.

AusCann’s joint venture partner, Fundación Daya has worked with the Chilean National Institute of Public Health to establish the special access scheme.

READ: AusCann Group's vertically integrated model provides point of difference in medicinal cannabis industry

A similar access scheme is used in Australia, which enables doctors to prescribe cannabinoid medicines prior to product registration.

Second cannabis crop is getting ready for harvest

AusCann and Fundación Daya’s joint venture, DayaCann, is the only company in Chile to hold a medical cannabis production licence.

DayaCann has a proven growing record with the first crop yielding over 400 kilograms of dried cannabis in 2017.

The second crop has been planted and is scheduled for harvest this year.

Aiming to supply medicinal cannabis products for the treatment of pain

AusCann managing director Elaine Darby said: “We are delighted with the establishment of this special access scheme.

“DayaCann’s second crop is almost ready for harvest, and this special access scheme will accelerate the joint venture’s goal of producing and supplying final dose form medicines for the treatment of pain in the Latin American market”

READ: AusCann Group to collaborate in enhancing medicinal cannabis production

The new special access scheme (SAS) will be applied to a medical cannabis product being locally produced at Knop Laboratories from cannabis supplied by DayaCann.

The SAS allows patients to access the products whilst clinical trials for product registration are being completed.

The patients can apply to their doctors for a prescription, which will be approved by the public health department on a case-by-case basis.

Phase II pain management trial progressing in cancer patients

Phase I trials have been completed, and a phase II trial is being conducted for pain management in cancer patients at a Chilean public health centre.

The cannabinoid medicines being supplied under the SAS will be mainly accessed by patients of 15 municipalities who participated in the funding of earlier plantings by Fundación Daya.

As a result of this participation, a specified number of residents will receive free access to a year’s treatment.

Patients outside of these municipalities will be able to buy the products in pharmacies with their official permit approved by the Chilean National Institute of Public Health.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

Laboratory testing
October 10 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
1541165310_canadian-flag-1.jpg
November 03 2018
Back Home Medical Cannabis Corp has agreed on a 24,000-kilogram three-year production and supply agreement
1542134062_Harvesting-hemp.jpg
November 14 2018
Ascent, viaThirty Eight Hemp Corp, will exploit the hemp market via its strategic relationship with AgTech Scientific

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use